DTx Pharma Completes $100M Series B Financing to Advance its FALCON Platform and Pipeline of RNA Therapeutics
DTx Pharma announced today the completion of a $100 million Series B financing. The financing was led by RA Capital […]
BlossomHill Therapeutics Completes $71M Series A Round to Progress Pipeline of Small Molecule Drugs for Oncology, Autoimmune Disorders
BlossomHill Therapeutics raised $71 million in a Series A financing round, led by Cormorant Asset Management LLC and joined by Hercules BioVentures […]
Caribou Bio Secures $115M to Advance CRISPR Platform and Allogeneic Cell Therapy Pipeline
Caribou Biosciences announced the successful completion of an oversubscribed $115 million Series C financing, co-led by new premier healthcare investors […]
Janux Therapeutics Concludes $56 Million Series A to Advance Novel Cancer Drug Candidates Using T Cell Engager (TRACTr) Technology
Janux Therapeutics announced the close of a $56 million Series A financing led by Avalon Ventures and joined by new […]
Artizan Biosciences Closes $11 Million Series A-2 Financing, Enters Option and License Agreement with Biohaven Therapeutics for IBD Therapies
Biotechnology company Artizan Biosciences announced the closing of an $11 million Series A-2 financing round, led by existing investors Hatteras […]
Merck Begins Tender Offer to Acquire Pandion Therapeutics
Merck (NYSE: MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash […]
InvestorWatch: UK Record Year in Life Science Sector Financings as Capital Circulates Looking for Rich Opportunity
With enormous sums of capital managed in the UK, its managers seek optimal scientific-based investments to not only progress health […]
UNSW & Garvan Institute Take Precision Medicine Revolution to War Against Pancreatic Cancer in Australia
Thanks to an $3.75 million grant injection from the Cancer Institute, NSW Translational Program, researchers and clinicians from UNSW and […]
Moderna Announces Strategies & Updates Associated with Variant-Specific Vaccine while Forecasting $18.4b in Revenue
Moderna Inc. (Nasdaq: MRNA), the biotechnology company with one of the authorized vaccines for COVID-19, completed the manufacturing of clinical […]
SoftBank Group to Move Billions into Biotech
Individuals from SoftBank Group Corp frequent the TrialSite News website on a daily basis. Clearly, there are individuals interested in the […]
